EA201170660A1 - Избирательная для erbb-3 (her3) комбинированная терапия - Google Patents

Избирательная для erbb-3 (her3) комбинированная терапия

Info

Publication number
EA201170660A1
EA201170660A1 EA201170660A EA201170660A EA201170660A1 EA 201170660 A1 EA201170660 A1 EA 201170660A1 EA 201170660 A EA201170660 A EA 201170660A EA 201170660 A EA201170660 A EA 201170660A EA 201170660 A1 EA201170660 A1 EA 201170660A1
Authority
EA
Eurasian Patent Office
Prior art keywords
her3
relates
her2
egfr
optionally
Prior art date
Application number
EA201170660A
Other languages
English (en)
Inventor
Байсун Ляо
Исянь Чжан
Original Assignee
Сантарис Фарма А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сантарис Фарма А/С filed Critical Сантарис Фарма А/С
Publication of EA201170660A1 publication Critical patent/EA201170660A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к фармацевтическим композициям для лечения и к способам лечения с помощью нацеленной на HER3 комбинированной терапии. Изобретение относится к фармацевтическим композициям, содержащим олигомер, нацеленный на мРНК HER3 (и, необязательно, одного или нескольких из HER2 и EGFR) в клетке, что приводит к уменьшенной экспрессии HER3 и, необязательно, HER2 и/или EGFR, и низкомолекулярный ингибитор протеинтирозинкиназы одной или нескольких рецепторных тирозинкиназ, что приводит к ингибированию передачи сигнала и/или интернализации димеров рецептора в клетку. Комбинированная терапия является преимущественной для ряда медицинских нарушений, таких как гиперпролиферативные нарушения (например, злокачественная опухоль). Изобретение относится к способам лечения гиперпролиферативных нарушений с помощью комбинации олигомера и ингибитора протеинтирозинкиназы.
EA201170660A 2008-11-07 2009-11-05 Избирательная для erbb-3 (her3) комбинированная терапия EA201170660A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11254908P 2008-11-07 2008-11-07
PCT/US2009/063357 WO2010054051A1 (en) 2008-11-07 2009-11-05 Erbb-3 (her3)-selective combination therapy

Publications (1)

Publication Number Publication Date
EA201170660A1 true EA201170660A1 (ru) 2011-12-30

Family

ID=42153234

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170660A EA201170660A1 (ru) 2008-11-07 2009-11-05 Избирательная для erbb-3 (her3) комбинированная терапия

Country Status (14)

Country Link
US (1) US20120004285A1 (ru)
EP (1) EP2376087A4 (ru)
JP (1) JP2012508244A (ru)
KR (1) KR20110086844A (ru)
CN (1) CN102223886A (ru)
AU (1) AU2009313510A1 (ru)
BR (1) BRPI0921407A2 (ru)
CA (1) CA2741050A1 (ru)
EA (1) EA201170660A1 (ru)
IL (1) IL212714A0 (ru)
MX (1) MX2011004869A (ru)
NZ (1) NZ592326A (ru)
TW (1) TW201021803A (ru)
WO (1) WO2010054051A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556673A (en) 2005-02-03 2010-03-26 Gen Hospital Corp Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
KR101354828B1 (ko) 2005-11-04 2014-02-18 와이어쓰 엘엘씨 ｍＴＯＲ 저해자, 헤르셉틴, 및/또는 ＨＫＩ-272의항신생물성 조합
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
EP3730139B1 (en) 2008-06-17 2023-08-16 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
KR101434009B1 (ko) 2008-08-04 2014-08-25 와이어쓰 엘엘씨 4-아닐리노-3-사이아노퀴놀린과 카페시타빈의 항신생물성 조합물
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画
CN108424456B (zh) 2011-11-23 2022-04-26 医学免疫有限责任公司 特异于her3的结合分子及其用途
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
CN108290930A (zh) * 2015-05-01 2018-07-17 胡文聪 Pink1 c末端结构域多肽及其用于癌症治疗的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176024A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of epidermal growth factor receptor (EGFR) gene expression using short interfering nucleic acid (siNA)
BR0309398A (pt) * 2002-04-19 2005-02-01 Cellular Genomics Inc Composto ou um seu sal, hidrato, solvato, forma cristalina, diastereÈmero, prodroga farmaceuticamente aceitável, ou misturas deles, composição farmacêutica, e, métodos para tratar uma condição envolvida com a cinase em um mamìfero, para tratar câncer, e para identificar uma cinase
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
WO2007031091A2 (en) * 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
WO2008109361A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc, Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
US20080287383A1 (en) * 2007-03-02 2008-11-20 Nastech Pharmaceutical Company Inc. Nucleic acid compounds for inhibiting erbb gene expression and uses thereof
EA200971049A1 (ru) * 2007-05-11 2010-04-30 Сантарис Фарма А/С Антагонисты phk и их применение для модуляции her3

Also Published As

Publication number Publication date
EP2376087A1 (en) 2011-10-19
CA2741050A1 (en) 2010-05-14
NZ592326A (en) 2013-01-25
WO2010054051A1 (en) 2010-05-14
EP2376087A4 (en) 2013-06-05
AU2009313510A1 (en) 2010-05-14
IL212714A0 (en) 2011-07-31
KR20110086844A (ko) 2011-08-01
US20120004285A1 (en) 2012-01-05
TW201021803A (en) 2010-06-16
CN102223886A (zh) 2011-10-19
MX2011004869A (es) 2011-06-20
BRPI0921407A2 (pt) 2019-09-24
JP2012508244A (ja) 2012-04-05

Similar Documents

Publication Publication Date Title
EA201170660A1 (ru) Избирательная для erbb-3 (her3) комбинированная терапия
CY1123625T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
EA201390550A1 (ru) Способы ингибирования пролиферации клеток в egfr-стимулируемых злокачественных опухолях
CY1120670T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα μονοπατιου ιστικου παραγοντα (tfpi)
WO2012016133A3 (en) Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers
EA201792304A1 (ru) Комбинированная терапия для лечения рака
MX2009011226A (es) Inhibidores especificos pdgfrbeta.
MY183404A (en) Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
WO2010048026A3 (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
MX2009012271A (es) Compuestos antagonistas de acido ribonucleico para la modulacion de her3.
AU2011332810A8 (en) Anti-IL-6 antibodies for the treatment of oral mucositis
EA201290138A1 (ru) Производные пиразола как модуляторы кальциевых каналов, активируемых высвобождением кальция
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
EA201290139A1 (ru) Модуляторы кальциевого канала, активируемого высвобождением кальция, представляющие собой производные пиразола, и способы лечения немелкоклеточного рака легких
HUP0302544A2 (hu) Receptor tirozinkináz-gátlókat és vérérképződés-gátlókat alkalmazó kombinált terápia
MY162132A (en) Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
EA201170155A1 (ru) Специфические антагонисты рецептора fgf-r4
WO2011084796A3 (en) Novel quinazoline derivatives
EP2476427A3 (en) A method of treating cancer comprising a VEGF-B antagonist
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
EA201171244A1 (ru) Способы лечения видов рака антисмысловыми олигонуклеотидами her3
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
NO20050528L (no) Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft
WO2007014335A3 (en) Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer